Gene Therapy for HIV and AIDS-Related Opportunistic Infections
Gene therapy was initially conceptualised as gene replacement treatment for genetic diseases, particularly diseases that are inherited in an autosomal recessive fashion and carry a significant morbidity, such as Cystic Fibrosis. However, as the field has expanded, it has taken advantage of the increasing knowledge base that there are genetic components to acquired disorders such as cancer, HIV infection and other infectious diseases. For example, those individuals that lack expression of the HIV chemokine co-receptor are resistant to HIV infection and progression of the disease to AIDS. Moreover, knowing the operative host defence mechanisms against certain pathogens may allow one to exploit these pathways for therapeutic purposes using gene transfer technology. This article will focus on the evolving strategies to use gene-based therapies in HIV infection, TB, and Pneumocystis carinii pneumonia.
KeywordsGene Therapy Pneumocystis Carinii Pneumonia Autosomal Recessive Fashion Pneumocystis Carinii Infection Increase Knowledge Base
Unable to display preview. Download preview PDF.
- 10.Morgan RA, Walker R. Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins. Hum Gene Ther. 1996; 7:1281–1306.Google Scholar
- 12.Bauer G, Valdez P, Kearns K, Bahner I, Wen SF, Zaia JA, Kohn DB. Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor- mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood. 1997; 89:2259–2267.PubMedGoogle Scholar
- 20.Furrer H, Egger M, Opravil M, Bernasconi E, Hirschel B, Battegay M, Telenti A, Vernazza PL, Rickenbach M, Flepp M, Malinverni R. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med. 1999; 340:1301–1306.PubMedCrossRefGoogle Scholar
- 21.Weverling GJ, Mocroft A, Ledergerber B, Kirk O, Gonzales-Lahoz J, d’Arminio MA, Proenca R, Phillips AN, Lundgren JD, Reiss P. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet. 1999; 353:1293–1298.PubMedCrossRefGoogle Scholar
- 25.Wallace JM, Hansen NI, Lavange L, Glassroth J, Browdy BL, Rosen MJ, Kvale PA, Mangura BT, Reichman LB, Hopewell PC. Respiratory disease trends in the Pulmonary Complications of HIV Infection Study cohort. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med. 1997; 155:72–80.PubMedGoogle Scholar
- 27.Greenberger MJ, Kunkel SL, Strieter RM, Lukacs NW, Bramson J, Gauldie J, Graham FL, Hitt M, Danforth JM, Standiford TJ. IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. J Immunol. 1996; 157:3006–3012.Google Scholar
- 28.Jaffe HA, Buhl R, Mastangeli A, Holroyd KJ, Saltini C, Czerski D, Jaffe HS, Kramer S, Sherwin S, Crystal RG. Organ specific cytokine therapy. Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon-gamma to the human lung. J Clin Invest. 1991; 88:297–302.PubMedCrossRefGoogle Scholar
- 29.Lei D, Lancaster JR, Jr., Joshi MS, Nelson S, Stoltz D, Bagby GJ, Odom G, Shellito JE, Kolls JK. Activation of alveolar macrophages and lung host defenses using transfer of the interferon-gamma gene. Am J Physiol. 1997; 272:L852–L859.Google Scholar